Abstract:The persistence of increased excitability and spontaneous activity in injured peripheral neurons is imperative for the development and persistence of many forms of neuropathic pain. This aberrant activity involves increased activity and/or expression of voltage-gated Na + and Ca 2+ channels and hyperpolarization activated cyclic nucleotide gated (HCN) channels as well as decreased function of K + channels. Because they display limited central side effects, peripherally restricted Na + and Ca 2+ channel blockers and K + channel activators offer potential therapeutic approaches to pain management. This review outlines the current status and future therapeutic promise of peripherally acting channel modulators. Selective blockers of Na v 1.3, Na v 1.7, Na v 1.8, Ca v 3.2, and HCN2 and activators of K v 7.2 abrogate signs of neuropathic pain in animal models. Unfortunately, their performance in the clinic has been disappointing; some substances fail to meet therapeutic end points whereas others produce dose-limiting side effects. Despite this, peripheral voltage-gated cation channels retain their promise as therapeutic targets. The way forward may include (i) further structural refinement of K + channel activators such as retigabine and ASP0819 to improve selectivity and limit toxicity; use or modification of Na + channel blockers such as vixotrigine, PF-05089771, A803467, PF-01247324, VX-150 or arachnid toxins such as Tap1a; the use of Ca 2+ channel blockers such as TTA-P2, TTA-A2, Z 944, ACT709478, and CNCB-2; (ii) improving methods for assessing “pain” as opposed to nociception in rodent models; (iii) recognizing sex differences in pain etiology; (iv) tailoring of therapeutic approaches to meet the symptoms and etiology of pain in individual patients via quantitative sensory testing and other personalized medicine approaches; (v) targeting genetic and biochemical mechanisms controlling channel expression using anti-NGF antibodies such as tanezumab or re-purposed drugs such as vorinostat, a histone methyltransferase inhibitor used in the management of T-cell lymphoma, or cercosporamide a MNK 1/2 inhibitor used in treatment of rheumatoid arthritis; (vi) combination therapy using drugs that are selective for different channel types or regulatory processes; (vii) directing preclinical validation work toward the use of human or human-derived tissue samples; and (viii) application of molecular biological approaches such as clustered regularly interspaced short palindromic repeats (CRISPR) technology.

Sphingosine pathway as a possible druggable target for pain management

Sphingosine-1-phosphate: a Potential Therapeutic Target for Rheumatoid Arthritis

The ceramide-S1P pathway as a druggable target to alleviate peripheral neuropathic pain

Dysregulation of sphingolipid metabolism in pain

Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain

Mesoporous Silica Particles As a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy.

S1P-S1PRs Alliance in Neuropathic Pain Processing

Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases

Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.

PD-1: A New Candidate Target for Analgesic Peptide Design

Explore the Role of the Sphingosine-1-Phosphate Signalling as a Novel Promising Therapeutic Target for the Management of Parkinson's Disease

Analgesia and peripheral c-fiber modulation by selective Nav1.8 inhibition in rhesus

The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases

Sphingosine 1-phosphate: Lipid signaling in pathology and therapy

S1P/S1PR1 signaling is involved in the development of nociceptive pain

Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch

Lipid raft disruption as an opportunity for peripheral analgesia

Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets

Differential contribution of sensory transient receptor potential channels in response to the bioactive lipid sphingosine-1-phosphate

CYP1B1-derived epoxides modulate the TRPA1 channel in chronic pain

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation